{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:27:43Z","timestamp":1773952063035,"version":"3.50.1"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/internalmedicine.51.6555","type":"journal-article","created":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T22:54:46Z","timestamp":1338504886000},"page":"1375-1378","source":"Crossref","is-referenced-by-count":12,"title":["Successful Treatment of a Mesangial Proliferative Glomerulonephritis with Interstitial Nephritis Associated with Castleman's Disease by an Anti-interleukin-6 Receptor Antibody (Tocilizumab)"],"prefix":"10.2169","volume":"51","author":[{"given":"Naoko","family":"Otani","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iekuni","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumi","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Muto","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kusano","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-830, 1956.","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4"},{"key":"2","unstructured":"2. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 20: 636-647, 1993."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chan KW, Chan MK, Choy DT. Nephrotic syndrome associated with angiofollicular lymph node hyperplasia. Pathology 19: 429-432, 1987.","DOI":"10.3109\/00313028709103897"},{"key":"4","unstructured":"4. Lui SL, Chan KW, Li FK, Cheng IK, Chan TM. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 78: 323-327, 1998."},{"key":"5","unstructured":"5. Komaba H, Nakazawa T, Yamaguchi Y, Kumagai S, Fukagawa M. Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases. Nephrology Dialysis Transplantation plus 1: 423-426, 2008 (in Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Said R, Tarawneh M. Membranoproliferative glomerulonephritis associated with multicentric angiofollicular lymph node hyperplasia. Case report and review of the literature. Am J Nephrol 12: 466-470, 1992.","DOI":"10.1159\/000168500"},{"key":"7","unstructured":"7. Xu D, Lv J, Dong Y, et al: Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant May 19, 2011 [Epub ahead of print]."},{"key":"8","unstructured":"8. Burger R, Wendler J, Antoni K, Helm G, Kalden JR, Gramatzki M. Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop. Ann Hematol 69: 25-31, 1994."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 46: 771-774, 2007.","DOI":"10.2169\/internalmedicine.46.6262"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ruef C, Budde K, Lacy J, et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 38: 249-257, 1990.","DOI":"10.1038\/ki.1990.193"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86: 592-599, 1990.","DOI":"10.1172\/JCI114749"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant 26: 599-609, 2011.","DOI":"10.1093\/ndt\/gfq427"},{"key":"13","unstructured":"13. Arimura H, Watanabe O, Arimura K, Maruyama I, Hokezu Y. Two cases of POEMS syndrome with increased vascular endothelial growth factor (VEGF). Rinsho Shinkeigaku 37: 817-823, 1997 (in Japanese)."},{"key":"14","unstructured":"14. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 59: 311-322, 1980."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"16","unstructured":"16. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68: 1580-1584, 2009."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/11\/51_51.6555\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:42:29Z","timestamp":1621446149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/11\/51_51.6555\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.51.6555","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}